After a phenomenal run from $2.52 on January 5 to a high of $51.17 on September 13, Tandem Diabetes Care (TNDM) stock slid to $28.45 on November 20.
Tandem stock managed to recover to $38.28 on December 3, but it’s fallen again in the last two sessions to its current level of $33.9.
Tandem Diabetes Care’s revenue rose an impressive 71.33% from $27.0 million in the third quarter of 2017 to $46.26 million in the third quarter of 2018. The company’s revenue in the fourth quarter of 2018 is expected to be $56.22 million.
The company’s gross margin expanded from 39% in the third quarter of 2017 to 47.11% in the third quarter of 2018. Its 2018 and 2019 gross margins are expected to be 47.05% and 51.76%, respectively.
Tandem Diabetes incurred a net loss of $73.03 million in 2017. In comparison, the company is expected to incur net losses of $135.92 million in 2018 and $44.16 million in 2019.
In December, of the 11 analysts covering Tandem Diabetes Care, eight have given the stock “buy” or higher ratings, and three have given it “hold” ratings. The mean rating for Tandem is 2, and its target price is $51.